Orphan Drug Designation from EMA & US FDA
The process of obtaining an Orphan Drug Designation (ODD) from the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) for a drug targeting a rare disease can be complex. Lobl Clinical Trials (GCT) offers valuable support in navigating the ODD application process. Here’s how we can assist:
EMA Orphan Drug Designation:
Eligibility Assessment: GCT helps assess if the drug and the target disease meet EMA’s criteria for orphan designation, which includes demonstrating the rarity of the disease and the potential therapeutic benefit of the drug.
Documentation Preparation: GCT assists in preparing a comprehensive ODD application dossier, which includes scientific data, and nonclinical and clinical trial information, as well as the rationale for the proposed treatment.
Regulatory Strategy: GCT advises on the appropriate regulatory strategy, addressing questions related to the drug’s development plan, potential challenges, and the optimal pathway for obtaining ODD.
Submission Management: GCT manages the submission process, ensuring that the application dossier is complete and follows EMA’s requirements. This involves preparing the application form, compiling relevant documents, and submitting them to EMA.
Communication with Authorities: GCT may serve as a point of contact between the sponsor and EMA, addressing any questions or clarifications requested by the agency during the review process.
U.S. FDA Orphan Drug Designation:
Eligibility Assessment: GCT assists in determining if the drug and the rare disease meet the FDA’s criteria for orphan designation, including prevalence, potential benefit, and lack of available treatment options.
Application Preparation: GCT supports the preparation of the Orphan Drug Designation application, which includes scientific data, preclinical and clinical trial information, and the rationale for pursuing orphan status.
Regulatory Strategy: GCT provides guidance on the regulatory strategy for ODD, ensuring that the application aligns with the drug’s development plan and the FDA’s requirements.
Application Submission: GCT manages the submission process, prepares the application package, and submits it to the FDA, ensuring compliance with the agency’s guidelines.
Interactions with the FDA: If the FDA requests additional information or clarification, GCT helps coordinate responses and interactions with the agency.
Benefits Communication: GCT assists in communicating the benefits of orphan designation to the sponsor, highlighting the incentives and market exclusivity that come with ODD.
In both cases, our expertise helps sponsors navigate the complex regulatory landscape, ensuring that the ODD application is accurate, complete, and compliant with the respective regulatory agency’s requirements. By providing comprehensive support, GCT plays a crucial role in facilitating the Orphan Drug Designation process and increasing the chances of a successful outcome for drugs targeting rare diseases.
Let’s keep in touch!
Get the latest news about GCT and the projects we support in a monthly email. View the mailing archive